Retatrutide Side Effects: What the Clinical Trials Reported

Where the retatrutide safety data comes from

Everything known about the side effects of retatrutide comes from trials run by its developer, Eli Lilly, under the research code LY3437943. Retatrutide is a single peptide that activates three receptors (GIP, GLP-1 and glucagon), and it is still investigational. No regulator has approved it, so there is no post-marketing surveillance data of the kind that exists for semaglutide or tirzepatide.

The main published and reported sources are:

• Phase 2 obesity trial (Jastreboff et al., New England Journal of Medicine, 2023): 338 adults with obesity or overweight, 48 weeks, doses of 1, 4, 8 and 12 mg once weekly against placebo.
• Phase 2 type 2 diabetes trial (Rosenstock et al., The Lancet, 2023): 281 adults with type 2 diabetes, 36 weeks, with dulaglutide 1.5 mg as an active comparator.
• Phase 2a liver fat substudy (Sanyal et al., Nature Medicine, 2024): 98 participants with fatty liver disease drawn from the obesity trial.
• Phase 3 TRIUMPH and TRANSCEND programmes: TRIUMPH-4 (knee osteoarthritis, topline December 2025), TRANSCEND-T2D-1 (type 2 diabetes, published in The Lancet in 2026), TRIUMPH-1 (obesity, topline May 2026), and TRIUMPH-2 and TRIUMPH-3 (topline July 2026).

Much of the phase 3 data is still in topline form from company announcements, not full peer-reviewed papers, so treat those percentages as preliminary. If you want the background on the molecule itself first, start with our explainer on what retatrutide is and how it works.

Gastrointestinal side effects: the most common retatrutide side effect

Every trial so far lists gastrointestinal events as the most frequent retatrutide side effect, which is what you would expect from anything that activates the GLP-1 receptor. In the phase 2 obesity trial these were nausea, diarrhoea, vomiting and constipation, mostly mild to moderate, more frequent at higher doses and concentrated in the escalation period.

The phase 3 numbers give the clearest picture. In TRIUMPH-1, Lilly reported these rates at the 12 mg dose against placebo over 80 weeks:

The type 2 diabetes trial TRANSCEND-T2D-1 (40 weeks) reported lower rates: nausea in 16.4%, 19.5% and 26.5% of the 4, 9 and 12 mg groups against 3.7% on placebo, and vomiting in 15.0% to 17.6% against 2.2%. Rates vary between trials because the populations, durations and escalation schedules differ, so compare within a trial rather than across them.

Dose escalation: what the trials changed to reduce side effects

The phase 2 obesity trial tested escalation directly. The 4 mg and 8 mg arms were split into groups that started at 2 mg and groups that started at 4 mg. Starting at 2 mg partly reduced the gastrointestinal events, which is why the phase 3 programme adopted a stepwise design. In TRANSCEND-T2D-1, for example, the reported regimen started at 2 mg and stepped up every four weeks.

Those are protocol details from controlled trials with medical supervision, and they are reported here only as study design. They are not a schedule for anyone to follow. The practical lesson for a reader is narrower: the tolerability numbers you see quoted depend heavily on how quickly the dose was raised, so a figure without its escalation scheme attached is not much use.

Retatrutide side effects on the heart: heart rate and cardiovascular events

Retatrutide raises resting heart rate, as GLP-1 based compounds generally do. In the phase 2 obesity trial the increase was dose dependent, peaked at around week 24 and declined after that. Reports of that trial put the peak rise in the range of roughly 5 to 10 beats per minute at the higher doses.

Cardiovascular outcomes are a separate question, and the answer is not in yet. TRIUMPH-3 enrolled people with obesity and established cardiovascular disease; analysts covering the July 2026 readout noted 27 major adverse cardiovascular events in the retatrutide group against 23 on placebo, while cautioning that the numbers were too small to draw conclusions. A dedicated cardiovascular and kidney outcomes trial, TRIUMPH-Outcomes, is still running, with sites in Australia including The Alfred, Royal North Shore and Fiona Stanley hospitals.

Dysesthesia: the side effect phase 2 did not predict

This is the finding we think gets the least attention. Dysesthesia means altered or unpleasant skin sensation, such as tingling, burning or sensitivity to touch. It was not a flagged signal in phase 2, but in TRIUMPH-4 it was reported in 8.8% of the 9 mg group and 20.9% of the 12 mg group, against 0.7% on placebo. Most events were mild and did not lead to stopping treatment.

TRIUMPH-1 reported dysesthesia in roughly one in ten participants at the highest doses, and TRANSCEND-T2D-1 in 2.3% to 4.5% of retatrutide groups against none on placebo. The mechanism has not been explained in published data. When a signal appears only once thousands of people are enrolled, it is a reminder that phase 2 safety tables are small.

Discontinuation rates and serious adverse events

Discontinuation because of adverse events is the most honest single tolerability number, because it counts people who stopped. The trials reported:

• Phase 2 obesity (48 weeks): 6% to 16% across retatrutide groups, none on placebo. Serious adverse events were 0% to 6% on retatrutide and 4% on placebo.
• TRIUMPH-1 (80 weeks): 4.1%, 6.9% and 11.3% for 4, 9 and 12 mg, against 4.9% on placebo.
• TRIUMPH-4 (68 weeks): 12.2% at 9 mg and 18.2% at 12 mg, against 4% on placebo.
• TRANSCEND-T2D-1 (40 weeks): 2.2%, 4.5% and 5.1% for 4, 9 and 12 mg, against 0% on placebo.

The liver fat substudy reported no hepatotoxicity signal through 48 weeks, and no ketoacidosis despite rises in beta-hydroxybutyrate. The pattern across the programme is consistent: tolerability worsens at the top dose, and 12 mg carries a noticeably higher dropout rate than 4 mg.

Is retatrutide safe? What is not known yet

Is retatrutide safe? Nobody can answer that yet, because no regulator has completed a review of it. The honest list of unknowns is long:

• Long-term side effects. The longest data runs to 104 weeks in a subgroup of TRIUMPH-1. Effects over many years have not been studied.
• Cancer. Searches for retatrutide side effects and cancer usually trace back to the incretin class: the US prescribing information for semaglutide and tirzepatide carries a boxed warning about thyroid C-cell tumours seen in rodents. We found no published human cancer signal for retatrutide in the trial data to date, and a 2025 mouse study in npj Metabolic Health and Disease actually reported slower tumour growth. Absence of a signal in trials of this length is not proof of absence.
• Cardiovascular outcomes. Pending TRIUMPH-Outcomes.
• Muscle and lean mass. A body composition substudy has been published for the type 2 diabetes trial, but data in large obesity populations is still limited.

There is also an Australian problem that has nothing to do with the molecule. In June 2026 the Victorian Department of Health reported six cases of acute liver injury since January in people using unapproved products labelled retatrutide, and said a contaminant was a possible cause. In September 2026 the TGA reported that a product sold as retatrutide, linked to a patient hospitalised with a torn oesophagus, contained no retatrutide at all, but a large dose of undeclared semaglutide. The TGA advises that retatrutide should not be used outside a clinical trial.

Retatrutide peptide side effects and laboratory research

The Australian cases above show why identity testing matters for any lab working with retatrutide. A vial that contains semaglutide instead of retatrutide has a different molecular mass, and mass spectrometry will show it. Every Chainwell Peptide lot is tested by an independent laboratory for identity (mass spectrometry) and purity (HPLC), and the lot number on each vial matches its certificate on our certificate of analysis lookup. Our guide to reading a peptide COA explains what those results should show.

For preparing vials in the lab, the retatrutide reconstitution calculator works out concentration from fill size and diluent volume, and bacteriostatic water is the usual diluent. Labs comparing incretin mechanisms often run a dual agonist such as research tirzepatide alongside it, and our retatrutide and tirzepatide comparison sets out how the trial safety profiles differ.

Research use only: Chainwell Peptide supplies retatrutide for laboratory research. It is not for human or veterinary use, and nothing on this page is medical or dosing advice.

Frequently asked questions